Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors

被引:4
|
作者
Yi, Min [1 ]
Lin, Heather [2 ]
Bedrosian, Isabelle [1 ]
Shen, Yu [2 ]
Hunt, Kelly K. [1 ]
Chavez-MacGregor, Mariana [3 ,4 ]
King, Tari A. [5 ,6 ]
Mittendorf, Elizabeth A. [5 ,6 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Hlth Serv Res, Houston, TX 77030 USA
[5] Brigham & Womens Hosp, Dept Surg, Div Breast Surg, 75 Francis St, Boston, MA 02115 USA
[6] Dana Farber Brigham & Womens Canc Ctr, Breast Oncol Program, Boston, MA 02215 USA
关键词
SURVIVAL; VALIDATION; BURDEN;
D O I
10.1245/s10434-019-07983-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The American Joint Committee on Cancer (AJCC) breast cancer pathological prognostic stage, which incorporates biologic factors, was developed using data from patients undergoing upfront surgery, and its application in patients receiving neoadjuvant chemotherapy (NAC) is unknown. We previously developed the Neo-Bioscore, incorporating clinical and pathological TNM categories with biologic factors, to improve the prognostic stratification of NAC patients. Objective. This study was undertaken to evaluate the use of available staging models incorporating biologic factors in NAC patients. Methods. Patients treated with NAC between 2005 and 2012 at MD Anderson (n = 2363) were staged using the Neo-Bioscore and the AJCC 8th edition: (1) clinical anatomic stage; (2) pathological anatomic stage; (3) clinical prognostic stage; and (4) pathological prognostic stage. Five-year disease-specific survival (DSS) and overall survival (OS) rates, along with Harrell's concordance index (C-index), were estimated. A National Cancer Database (NCDB) cohort (n = 12,887) treated with NAC between 2010 and 2013 was used for validation. Results. In the MD Anderson cohort, staging systems incorporating biologic factors better predicted DSS (bias-corrected C-index: pathological prognostic stage = 0.8026; Neo-Bioscore = 0.7483) and OS (bias-corrected C-index: pathological prognostic stage = 0.7780; Neo-Bioscore = 0.7260) than those using anatomic factors only. Similar results were seen in the NCDB cohort. In pairwise comparisons, the pathological prognostic stage was significantly better (p < 0.0001) than other staging systems in all comparisons except for OS in the NCDB cohort, where it was not significantly different than the Neo-Bioscore (p = 0.2). Conclusion. Biologic factors are important for determining prognosis in patients receiving NAC. These data indicate that the 8th edition AJCC pathological prognostic stage is applicable in these patients.
引用
收藏
页码:359 / 366
页数:8
相关论文
共 50 条
  • [41] Quality of life in patients with breast cancer with neoadjuvant chemotherapy: a systematic review
    Zhao, Yueqiu
    Chen, Licong
    Zheng, Xiaoqing
    Shi, Yulan
    BMJ OPEN, 2022, 12 (11):
  • [42] Lymph node ratio as an alternative to pN staging for predicting prognosis after neoadjuvant chemotherapy in breast cancer
    Cho, Dong Hui
    Bae, Soo Youn
    You, Ji Young
    Kim, Hong Kyu
    Chang, Young Woo
    Choi, Yoo Jin
    Woo, Sang Uk
    Son, Gil Soo
    Lee, Jae Bok
    Bae, Jeoung Won
    Jung, Seung Pil
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2018, 34 (06): : 341 - 347
  • [43] Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy
    Pataer, Apar
    Weissferdt, Annikka
    Vaporciyan, Ara A.
    Correa, Arlene M.
    Sepesi, Boris
    Wistuba, Ignacio I.
    Heymach, John, V
    Cascone, Tina
    Swisher, Stephen G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (08) : 1289 - 1297
  • [44] Tailoring neoadjuvant chemotherapy for patients with breast cancer who have achieved pathologic complete response
    Li, Xianjun
    Liu, Yang
    Shan, Ming
    Xu, Biagqi
    Lu, Yubo
    Zhang, Guoqiang
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 1205 - 1214
  • [45] Outcome of radiotherapy for clinically overt metastasis to the internal mammary lymph node in patients receiving neoadjuvant chemotherapy and breast cancer surgery
    Kim, Haeyoung
    Kim, Su Ssan
    Lee, Ik Jae
    Shin, Kyung Hwan
    Kim, Kyubo
    Jung, Jinhong
    Kim, Yong Bae
    Chang, Jee Suk
    Choi, Doo Ho
    Park, Won
    Yang, Kyungmi
    Chang, Ji Hyun
    Cha, Jihye
    Kim, Jin Hee
    Lee, Dong Soo
    BREAST, 2021, 55 : 112 - 118
  • [46] Association between Changes in Serum 25-Hydroxyvitamin D Levels and Survival in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
    Kim, Ji Su
    Haule, Caspar Christian
    Kim, Joo Heung
    Lim, Sung Mook
    Yoon, Kwang Hyun
    Kim, Jee Ye
    Park, Hyung Seok
    Park, Seho
    Kim, Seung Il
    Cho, Young Up
    Park, Byeong-Woo
    JOURNAL OF BREAST CANCER, 2018, 21 (02) : 134 - 141
  • [47] Role of neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: a meta-analysis
    Zhou, Qiong
    Dong, Jie
    Sun, Qingqing
    Lu, Nannan
    Pan, Yueyin
    Han, Xinghua
    BMJ OPEN, 2021, 11 (09):
  • [48] Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy
    Rella, Rossella
    Bu, Enida
    Belli, Paolo
    Scrofani, Anna Rita
    Petta, Federica
    Borghetti, Alberto
    Marazzi, Fabio
    Valentini, Vincenzo
    Manfredi, Riccardo
    DIAGNOSTIC AND INTERVENTIONAL IMAGING, 2022, 103 (10) : 486 - 494
  • [49] A detailed description of the distress trajectory from pre- to post-treatment in breast cancer patients receiving neoadjuvant chemotherapy
    Lacourt, Tamara E.
    Koncz, Zsuzsa
    Tullos, Emily A.
    Tripathy, Debu
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 197 (02) : 299 - 305
  • [50] Clinical Outcome and Prognostic Factors in Iranian Breast Cancer Patients After Neoadjuvant Chemotherapy: A Comparative Matched Study
    Kashi, Amir Shahram Yousefi
    Montazeri, Rezvan
    Rakhsha, Afshin
    INTERNATIONAL JOURNAL OF CANCER MANAGEMENT, 2018, 11 (05)